{"name":"ibrahim doğru","slug":"ibrahim-do-ru","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Naproxen Sodium + Codeine Phosphate","genericName":"Naproxen Sodium + Codeine Phosphate","slug":"naproxen-sodium-codeine-phosphate","indication":"Moderate to moderately severe pain","status":"marketed"}]}],"pipeline":[{"name":"Naproxen Sodium + Codeine Phosphate","genericName":"Naproxen Sodium + Codeine Phosphate","slug":"naproxen-sodium-codeine-phosphate","phase":"marketed","mechanism":"Naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and pain, while codeine phosphate acts as an opioid agonist to enhance analgesia through central nervous system depression.","indications":["Moderate to moderately severe pain","Acute pain conditions requiring combined NSAID and opioid analgesia"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}